KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$12.77 USD
-0.28 (-2.15%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $12.77 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, KalVista Pharmaceuticals, Inc. has a market cap of $651.90M, which represents its share price of $13.05 multiplied by its outstanding shares number of 49.95M. As a small-cap company, KALV's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
KALV 12.77 -0.28(-2.15%)
Will KALV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KALV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KALV
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KALV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for KALV
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV ...
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)
KalVista (KALV) Advances in Europe with Sebetralstat Approval
KalVista, Biogen, Ionis get EU positive opinions for key drugs
KalVista (KALV) Awaits EU Approval for Sebetralstat for Hereditary Angioedema | KALV Stock News